MULTIPLE MYELOMA

The approval follows a unanimous vote by the FDA’s Oncologic Drugs Advisory Committee where they decided the benefits of cilta-cel outweigh the risks for this patient population.

Idecabtagene vicleucel (ide-cel) demonstrated a 51% reduction in risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the SWOG S0777 and MAIA trials in transplant-ineligible newly diagnosed multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Abdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, explores how CAR-T therapy may impact the future treatment landscape for R/R MM, including current unmet needs and clinical pearls for community oncologists treating patients with R/R MM.

Binod Dhakal, MD, shares clinical perspectives on using CAR-T therapy in R/R MM, highlighting the implications of the latest data for community oncologists and their patients.

Binod Dhakal, MD, discusses the current approach to sequencing CAR-T therapy for patients with R/R MM, including the impact of emerging bispecific antibodies and the potential role of CAR-T in earlier lines of therapy.

Binod Dhakal, MD, explores clinicians' safety concerns with using CAR-T therapy in R/R MM, including notable adverse events from recent clinical data and strategies for managing these events in practice.

Binod Dhakal, MD, discusses the latest results from the KarMMA-3 study, which investigated idecabtagene vicleucel (ide-cel) for patients with R/R MM, covering study design, patient population, and key takeaways.

Binod Dhakal, MD, reviews the latest results from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel (cilta-cel) versus standard of care in patients with R/R MM, including study design, patient population, and key efficacy findings.

Binod Dhakal, MD, explores the role of CAR-T cell therapy in R/R MM, including an overview of the process, patient selection criteria, and identifying suitable candidates.

Binod Dhakal, MD, discusses the current standard of care for R/R MM, highlighting how treatment decision-making changes for patients who are refractory to lenalidomide and/or bortezomib.

Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.

March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.

P-BCMA-ALLO1 was granted an FDA orphan drug designation for the treatment of patients with relapsed/refractory multiple myeloma and is being evaluated in a phase 1 trial.

Adam D. Cohen, MD, discusses the different chimeric antigen receptor T-cell therapies used for multiple myeloma treatment and delves into their potential benefits and risks.

During an Oncologic Drugs Advisory Committee Meeting, the FDA found that ciltacabtagene autoleucel has a favorable benefit/risk profile in relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy and are refractory to lenalidomide.

Introducing a checkpoint inhibitor like nivolumab for patients where chimeric antigen receptor T-cell therapy failed in multiple myeloma is a potential area of interest for researchers.

Susan Bal, MD, discussed GPRC5D as an immunotherapeutic target in multiple myeloma and findings from a phase 1 study evaluating a novel CAR T-cell therapy working to target GPRC5D.

Adam D. Cohen, MD, discusses the new era of multiple myeloma treatment with bispecifics and CAR T-cell therapy.

Belantamab mafodotin plus pomalidomide and dexamethasone significantly extended progression-free survival in multiple myeloma, offering a potential new treatment option with different mechanisms of action.

Balancing cost and efficiency remains at the crux of autologous stem cell transplants for multiple myeloma treatment.

The investigational new drug application for CLN-619 has been granted clearance from the FDA, marking it as a potential for the treatment of relapsed/refractory multiple myeloma.

Adam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.

The natural killer cell therapy IDP-023 is being studied in a phase 1 trial for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma.

In an interview with Targeted Oncology, Binod Dhakal, MD, MS, discussed the phase 2 IMPEDE trial, focusing on the treatment regimen Isa-EloPD for patients with relapsed/refractory multiple myeloma.